Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fa M ^a   Puzzo, D ^a,b   Piacentini, R ^c   Staniszewski, A ^a   Zhang, H ^a   Baltrons, M A ^a,d   Li Puma, D D ^c   Chatterjee, I ^a,e   Li, J ^a,f   Saeed, F ^a   Berman, H L ^a   Ripoli, C ^c   Gulisano, W ^b   Gonzalez, J ^g   Tian, H ^h   Costa, J A ^a   Lopez, P ^e   Davidowitz, E ^e   Yu, W H ^a   Haroutunian, V ⁱ   Brown, L M ^j   Palmeri, A ^b   Sigurdsson, E M ^k   Duff, K E ^a   Teich, A F ^a   Honig, L S ^a   Sierks, M ^g   Moe, J G ^e   D'Adamio, L ^l   Grassi, C ^m,n   Kanaan, N M ⁿ   Fraser, P E ^o   Arancio, O ^a   more..

^a Department of Medicine   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Oligomerix   (United States)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

^g ROCKEFELLER UNIVERSITY   (United States)

^h ARIZONA STATE UNIVERSITY   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j NYU Langone Medical Center ^*  (United States)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m IRCCS SAN RAFFAELE PISANA   (Italy)

ⁿ MICHIGAN STATE UNIVERSITY   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DISEASE MODEL; EXTRACELLULAR SPACE; HIPPOCAMPUS; LONG TERM POTENTIATION; MEMORY; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; PROTEIN MULTIMERIZATION; PROTEINOSIS; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SPACE; HIPPOCAMPUS; LONG-TERM POTENTIATION; MEMORY; MICE; NEURONS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN MULTIMERIZATION; TAU PROTEINS;

EID: 84955306758     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19393     Document Type: Article

References (66)

1. Sahara, N., et al. Assembly of two distinct dimers and higher-order oligomers from full-length tau. The European journal of neuroscience 25, 3020-3029 (2007).
2. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R. & Kayed, R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041 (2010).
3. Xu, S., Brunden, K.R., Trojanowski, J.Q. & Lee, V.M. Characterization of tau fibrillization in vitro. Alzheimer's & dementia: the journal of the Alzheimer's Association 6, 110-117 (2010).
4. Chromy, B.A. et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749-12760 (2003).
5. Morris, M., Maeda, S., Vossel, K. & Mucke, L. The many faces of tau. Neuron 70, 410-426 (2011).
6. Clavaguera, F., Grueninger, F. & Tolnay, M. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Neuropharmacology 76 Pt A, 9-15 (2014).
7. Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W. & Hanger, D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14, 389-394 (2013).
8. Yamada, K., et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med 211, 387-93 (2014).
9. Phillips, R.G. & LeDoux, J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behavioral neuroscience 106, 274-285 (1992).
10. Berger, Z., et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. The Journal of neuroscience: the official journal of the Society for Neuroscience 27, 3650-3662 (2007).
11. Brunden, K.R., Trojanowski, J.Q. & Lee, V.M. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. Journal of Alzheimer's disease: JAD 14, 393-399 (2008).
12. Lasagna-Reeves, C.A., et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology (2012).
13. Patterson, K.R. et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. The Journal of biological chemistry 286, 23063-23076 (2011).
14. Magnoni, S. et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain: a journal of neurology 135, 1268-1280 (2012).
15. Castillo-Carranza, D.L. et al. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. Journal of Alzheimer's disease: JAD 40 Suppl 1, S97-S111 (2014).
16. Gendreau, K.L. & Hall, G.F. Tangles, Toxicity, and Tau Secretion in AD-New Approaches to a Vexing Problem. Frontiers in neurology 4, 160 (2013).
17. Frost, B., Jacks, R.L. & Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. The Journal of biological chemistry 284, 12845-12852 (2009).
18. Wu, J.W. et al. Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons. The Journal of biological chemistry 288, 1856-1870 (2013).
19. Michel, C.H. et al. Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. The Journal of biological chemistry 289, 956-967 (2014).
20. Amadoro, G. et al. Role of N-terminal tau domain integrity on the survival of cerebellar granule neurons. Cell death and differentiation 11, 217-230 (2004).
21. LaPointe, N.E. et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. Journal of neuroscience research 87, 440-451 (2009).
22. Kanaan, N.M. et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. The Journal of neuroscience: the official journal of the Society for Neuroscience 31, 9858-9868 (2011).
23. Kanaan, N.M. et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiology of aging 33, e815-830 (2012).
24. Sokolow, S. et al. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. Journal of neurochemistry 133, 368-379 (2015).
25. Kim, W., Lee, S. & Hall, G.F. Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert. FEBS letters 584, 3085-3088 (2010).
26. Decker, J.M. et al. Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca dysregulation. Acta neuropathologica communications 3, 23 (2015).
27. Lasagna-Reeves, C.A. et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific reports 2, 700 (2012).
28. Goedert, M. et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553 (1996).
29. Kampers, T., Friedhoff, P., Biernat, J., Mandelkow, E.M. & Mandelkow, E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS letters 399, 344-349 (1996).
30. Perez, M., Valpuesta, J.M., Medina, M., Montejo de Garcini, E. & Avila, J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. Journal of neurochemistry 67, 1183-1190 (1996).
31. Wilson, D.M. & Binder, L.I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. The American journal of pathology 150, 2181-2195 (1997).
32. Santa-Maria, I., Hernandez, F., Martin, C.P., Avila, J. & Moreno, F.J. Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 43, 2888-2897 (2004).
33. Kumar, S. et al. Stages and Conformations of Tau Repeat Domain during Aggregation and Effects on Neuronal Toxicity. The Journal of biological chemistry (2014).
34. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
35. Cirrito, J.R. et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922 (2005).
36. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nature cell biology 11, 909-913 (2009).
37. de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012).
38. Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M. & Diamond, M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. The Journal of biological chemistry 287, 19440-19451 (2012).
39. Kim, W. et al. Interneuronal transfer of human tau between Lamprey central neurons in situ. Journal of Alzheimer's disease: JAD 19, 647-664 (2010).
40. Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PloS one 7, e31302 (2012).
41. Braak, E., Braak, H. & Mandelkow, E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta neuropathologica 87, 554-567 (1994).
42. Ward, S.M. et al. TOC1: characterization of a selective oligomeric tau antibody. Journal of Alzheimer's disease: JAD 37, 593-602 (2013).
43. Mufson, E.J., Ward, S. & Binder, L. Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease. Neurodegener Dis 13, 151-153 (2014).
44. Spires-Jones, T.L., Stoothoff, W.H., de Calignon, A., Jones, P.B. & Hyman, B.T. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32, 150-159 (2009).
45. Kopeikina, K.J., Hyman, B.T. & Spires-Jones, T.L. Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci 3, 223-233 (2012).
46. Mirbaha, H., Holmes, B.B., Sanders, D.W., Bieschke, J. & Diamond, M.I. Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation. The Journal of biological chemistry 290, 14893-14903 (2015).
47. Holmes, B.B. & Diamond, M.I. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. The Journal of biological chemistry 289, 19855-19861 (2014).
48. Polydoro, M., Acker, C.M., Duff, K., Castillo, P.E. & Davies, P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. The Journal of neuroscience: the official journal of the Society for Neuroscience 29, 10741-10749 (2009).
49. Andorfer, C. et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86, 582-90 (2003).
50. Ninan, I. & Arancio, O. Presynaptic CaMKII Is Necessary for Synaptic Plasticity in Cultured Hippocampal Neurons. Neuron 42, 129-141 (2004).
51. Antonova, I. et al. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science 294, 1547-1550 (2001).
52. Schipke, C.G., Prokop, S., Heppner, F.L., Heuser, I. & Peters, O. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. Dementia and geriatric cognitive disorders 31, 139-145 (2011).
53. Mattsson, N. et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & dementia: the journal of the Alzheimer's Association 7, 386-395 e386 (2011).
54. Furukawa, Y., Kaneko, K. & Nukina, N. Tau protein assembles into isoform-and disulfide-dependent polymorphic fibrils with distinct structural properties. The Journal of biological chemistry 286, 27236-27246 (2011).
55. Tian, H. et al. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol 2013, 260787 (2013).
56. Ward, S.M., Himmelstein, D.S., Lancia, J.K. & Binder, L.I. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40, 667-671 (2012).
57. Wang, M.S., Zameer, A., Emadi, S. & Sierks, M.R. Characterizing antibody specificity to different protein morphologies by AFM. Langmuir 25, 912-918 (2009).
58. Puzzo, D. et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. The Journal of neuroscience: the official journal of the Society for Neuroscience 28, 14537-14545 (2008).
59. Alamed, J., Wilcock, D.M., Diamond, D.M., Gordon, M.N. & Morgan, D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nature protocols 1, 1671-1679 (2006).
60. Fiorito, J. et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. European journal of medicinal chemistry 60, 285-294 (2013).
61. Ivanovova, N., Handzusova, M., Hanes, J., Kontsekova, E. & Novak, M. High-yield purification of fetal tau preserving its structure and phosphorylation pattern. J Immunol Methods 339, 17-22 (2008).
62. Csokova, N. et al. Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. Protein Expr Purif 35, 366-372 (2004).
63. Moran, D., Cross, T., Brown, L.M., Colligan, R.M. & Dunbar, D. Data-independent acquisition (MSE) with ion mobility provides a systematic method for analysis of a bacteriophage structural proteome. Journal of Virological Methods 195, 9-17 (2014).
64. Fa, M. et al. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. Journal of visualized experiments: JoVE (2010).
65. Piacentini, R. et al. HSV-1 promotes Ca2+mediated APP phosphorylation and Abeta accumulation in rat cortical neurons. Neurobiology of aging 32, 2323 e2313-2326 (2011).
66. Ripoli, C. et al. Intracellular accumulation of amyloid-beta (Abeta) protein plays a major role in Abeta-induced alterations of glutamatergic synaptic transmission and plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 34, 12893-12903 (2014